Intrathecal Morphine in Knee Arthroplasty
Information source: University College Hospital Galway
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain, Postoperative; Arthroplasty, Replacement, Knee
Intervention: intra thecal morphine (Drug); intra thecal morphine (Drug); intra thecal morphine (Drug)
Sponsored by: University College Hospital Galway
Official(s) and/or principal investigator(s):
Patrick D Hassett, MD, Principal Investigator, Affiliation: Department of Anaesthesia, UCHG
John Laffey, MD, Study Chair, Affiliation: Department of Anaesthesia,UCHG
Brian Kinirons, MD, Study Director, Affiliation: Dept of Anaesthesia , UCHG
This study is designed to explore the efficacy lower doses of intra-spinal morphine for pain
relief and side effect profiles of same in the setting of Total Knee Replacement. We
hypothesized that a dose greater than that used in Total Hip Replacement was needed and
wished to find a dose which was effective but had a low side effect profile.
Official title: Determination of the Efficacy and Side-Effect Profile of Lower Doses of Intrathecal Morphine in Patients Undergoing Total Knee Arthroplasty
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: pain
nausea and vomiting
Minimum age: 18 Years.
Maximum age: N/A.
- Patients for elective total knee arthroplasty
- No contraindication to spinal
- No allergy to morphine, rescue analgesia or anti-emesis treatment.
Locations and Contacts
Starting date: July 2003
Last updated: June 9, 2008